Last 12 months
Inside the activity.
2 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2026 Filed Mar 11, 2026 17:45 UTC |
Driscoll Michael JosephDirector
|
PurchaseClass A Common Stock | 10,000 | $2.67 | $26,688.00 |
DisclosureSEC source: 0002064832-26-000127 · form4.xml · nonDerivative · entry 1 Driscoll Michael Joseph · CIK 0001912097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,707 Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:45 UTC |
Leibowitz Arthur SDirector
|
PurchaseClass A Common Stock | 5,000 | $2.68 | $13,405.00 |
DisclosureSEC source: 0002064832-26-000129 · form4.xml · nonDerivative · entry 1 Leibowitz Arthur S · CIK 0001467329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,014 Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 16:55 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 700 | $3.21 | $2,247.00 |
DisclosureSEC source: 0002064832-26-000093 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,524 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:26 UTC |
Lustig GarrettDirector
|
GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000050 · form4.xml · nonDerivative · entry 1 Lustig Garrett · CIK 0002044364 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,742 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:28 UTC |
Cavorsi RobertVice President, Strategy
|
GrantStock Option (Right to Buy) · Derivative | 53,452 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000061 · form4.xml · derivative · entry 4 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,452 Underlying: Class A Common Stock · 53,452 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:28 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 5,432 | $3.84 | $20,858.88 |
DisclosureSEC source: 0002064832-26-000061 · form4.xml · nonDerivative · entry 3 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,115 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:28 UTC |
Cavorsi RobertVice President, Strategy
|
GrantClass A Common Stock | 16,290 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000061 · form4.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,547 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:28 UTC |
Cavorsi RobertVice President, Strategy
|
GrantClass A Common Stock | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000061 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,257 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:27 UTC |
Driscoll Michael JosephDirector
|
GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000056 · form4.xml · nonDerivative · entry 1 Driscoll Michael Joseph · CIK 0001912097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,707 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:26 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantStock Option (Right to Buy) · Derivative | 23,162 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000053 · form4.xml · derivative · entry 4 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,162 Underlying: Class A Common Stock · 23,162 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:26 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 3,741 | $3.84 | $14,365.44 |
DisclosureSEC source: 0002064832-26-000053 · form4.xml · nonDerivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,163 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:26 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantClass A Common Stock | 11,218 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000053 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,904 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:26 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantClass A Common Stock | 40,625 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000053 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,686 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:27 UTC |
Leibowitz Arthur SDirector
|
GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000054 · form4.xml · nonDerivative · entry 1 Leibowitz Arthur S · CIK 0001467329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,014 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:29 UTC |
Freedman LoriChief Admin. and Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 115,812 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000062 · form4.xml · derivative · entry 4 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,812 Underlying: Class A Common Stock · 115,812 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:29 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 14,267 | $3.84 | $54,785.28 |
DisclosureSEC source: 0002064832-26-000062 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,023,355 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:29 UTC |
Freedman LoriChief Admin. and Legal Officer
|
GrantClass A Common Stock | 42,780 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000062 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,037,622 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:29 UTC |
Freedman LoriChief Admin. and Legal Officer
|
GrantClass A Common Stock | 203,125 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000062 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,842 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:27 UTC |
Giacomin Jon LDirector
|
GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000055 · form4.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,026 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Francisco DavidChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 111,358 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000060 · form4.xml · derivative · entry 4 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,358 Underlying: Class A Common Stock · 111,358 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 14,541 | $3.84 | $55,837.44 |
DisclosureSEC source: 0002064832-26-000060 · form4.xml · nonDerivative · entry 3 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,020 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Francisco DavidChief Financial Officer
|
GrantClass A Common Stock | 43,602 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000060 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,561 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Francisco DavidChief Financial Officer
|
GrantClass A Common Stock | 195,312 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000060 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 701,959 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Bilbo PatrickChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,267 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000058 · form4.xml · derivative · entry 4 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,267 Underlying: Class A Common Stock · 120,267 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 16,212 | $3.84 | $62,254.08 |
DisclosureSEC source: 0002064832-26-000058 · form4.xml · nonDerivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,127,985 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Bilbo PatrickChief Operating Officer
|
GrantClass A Common Stock | 48,612 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000058 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144,197 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Bilbo PatrickChief Operating Officer
|
GrantClass A Common Stock | 210,937 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000058 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,095,585 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Grow BrianChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 133,630 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000059 · form4.xml · derivative · entry 4 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,630 Underlying: Class A Common Stock · 133,630 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 11,768 | $3.84 | $45,189.12 |
DisclosureSEC source: 0002064832-26-000059 · form4.xml · nonDerivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 899,355 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Grow BrianChief Commercial Officer
|
GrantClass A Common Stock | 48,330 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000059 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911,123 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC |
Grow BrianChief Commercial Officer
|
GrantClass A Common Stock | 234,375 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000059 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862,793 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:27 UTC |
Gillheeney Gary S.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 507,795 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000057 · form4.xml · derivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,795 Underlying: Class A Common Stock · 507,795 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:27 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 90,398 | $3.84 | $347,128.32 |
DisclosureSEC source: 0002064832-26-000057 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,231,112 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:27 UTC |
Gillheeney Gary S.Director · President and CEO
|
GrantClass A Common Stock | 186,968 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000057 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,321,510 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:27 UTC |
Gillheeney Gary S.Director · President and CEO
|
GrantClass A Common Stock | 890,625 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000057 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,134,542 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:26 UTC |
Quintero GilbertoDirector
|
GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000052 · form4.xml · nonDerivative · entry 1 Quintero Gilberto · CIK 0001927023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,073 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:26 UTC |
Duraibabu PrathyushaDirector
|
GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000051 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,047 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:25 UTC |
Korfin Michele IleneDirector
|
GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000049 · form4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,073 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:34 UTC Amendment |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 5,487 | $3.84 | $21,070.08 |
DisclosureSEC source: 0002064832-26-000087 · form4a.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,224 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:34 UTC Amendment |
Cavorsi RobertVice President, Strategy
|
GrantClass A Common Stock | 16,454 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000087 · form4a.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,711 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:35 UTC Amendment |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 3,778 | $3.84 | $14,507.52 |
DisclosureSEC source: 0002064832-26-000092 · form4a.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,238 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:35 UTC Amendment |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantClass A Common Stock | 11,330 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000092 · form4a.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,016 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:34 UTC Amendment |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 14,411 | $3.84 | $55,338.24 |
DisclosureSEC source: 0002064832-26-000086 · form4a.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,023,643 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:34 UTC Amendment |
Freedman LoriChief Admin. and Legal Officer
|
GrantClass A Common Stock | 43,212 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000086 · form4a.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,038,054 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 91,311 | $3.84 | $350,634.24 |
DisclosureSEC source: 0002064832-26-000091 · form4a.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,232,087 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment |
Gillheeney Gary S.Director · President and CEO
|
GrantClass A Common Stock | 188,856 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000091 · form4a.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,323,398 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 11,887 | $3.84 | $45,646.08 |
DisclosureSEC source: 0002064832-26-000090 · form4a.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 899,724 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment |
Grow BrianChief Commercial Officer
|
GrantClass A Common Stock | 48,818 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000090 · form4a.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911,611 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 16,375 | $3.84 | $62,880.00 |
DisclosureSEC source: 0002064832-26-000089 · form4a.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,128,312 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment |
Bilbo PatrickChief Operating Officer
|
GrantClass A Common Stock | 49,102 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000089 · form4a.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144,687 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.